Medication info
Romethan Tablet 10/40 mg

Romethan Tablet 10/40 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›13.888mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
Brownish-red round film-coated tablet
Packaging
28 tablets/box [14 tablets/PTP×2]
Approval status
Active

MFDS item code 201405130 · Approved 2014.11.03 · Insurance code 671704360

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil) before administering this medicine; however, switching directly to this medicine may be considered if blood pressure is not controlled with monotherapy using the individual components. The maximum dose of this medicine is 10/40 mg. Since the maximum antihypertensive effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ○Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ○Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See Section 2. Patients Who Should Not Take This Medicine under Precautions for Use.) ○Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored more frequently and closely in older adults.
Child dose
○Children: The safety and efficacy in pediatric patients under 18 years of age have not been established.

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

Amlodipine or olmesartan medoxomil is used when blood pressure is not adequately controlled with monotherapy in patients with essential hypertension. These medications effectively control blood pressure by dilating blood vessels or lowering blood pressure, thus helping to prevent cardiovascular diseases. They are drugs that contribute to maintaining health through proper blood pressure management.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil) before administering this medicine; however, switching directly to this medicine may be considered if blood pressure is not controlled with monotherapy using the individual components. The maximum dose of this medicine is 10/40 mg. Since the maximum antihypertensive effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ○Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ○Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See Section 2. Patients Who Should Not Take This Medicine under Precautions for Use.) ○Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored more frequently and closely in older adults.

Child dose

○Children: The safety and efficacy in pediatric patients under 18 years of age have not been established.

Precautions

This medication can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. It should not be administered to individuals with an allergy to the active ingredients or similar substances, pregnant or breastfeeding women, individuals with severe liver disease, aortic stenosis, biliary obstruction, those undergoing kidney dialysis, individuals in shock, or specific diabetic patients. Patients with hypotension due to a deficit in fluid or salt or extreme vasodilation, patients with severe coronary artery disease, congestive heart failure, decreased kidney function, or liver dysfunction should use this medication cautiously. If symptoms of hypotension occur, immediate treatment and observation are necessary. Various side effects such as dizziness, headache, blood pressure drops, digestive disorders, skin rashes, and swelling may appear while taking this medication, so consult a healthcare professional if symptoms are severe or persistent. Abrupt discontinuation of beta-blockers can be dangerous; therefore, although this medication is not a beta-blocker, the dosage should be reduced gradually when discontinuing beta-blockers. This medication may interact with other blood pressure medications, diuretics, antibiotics, grapefruit juice, etc., so it is essential to inform your healthcare provider of any other medications being taken, especially avoiding grapefruit juice. Pregnant women should not use this medication, and those planning to become pregnant or who are pregnant should switch to safer alternatives. During breastfeeding, because this medication can be transferred into breast milk, it is advisable to either stop breastfeeding or discontinue the medication. Safety and efficacy have not been established in pediatric patients under 18 years of age, so it is not recommended. Elderly patients may have decreased kidney and liver function, so treatment should start at lower doses and their conditions should be monitored closely. In cases of overdose, hypotension and abnormal heart rate may occur, requiring immediate medical attention and appropriate treatment, which may include medications to raise blood pressure. This medication should be stored out of the reach of children, avoiding moisture, heat, and direct sunlight.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • sensory loss
  • syncope
Show 87 more
  • vertigo
  • palpitations
  • rapid heartbeat
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • epigastric pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • lumbago
  • increased urinary frequency
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • weakness
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • worsening of cerebral infarction
  • gum bleeding
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • side pain
  • systemic pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • herpes zoster
  • diplopia
  • insomnia
  • weakness
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute kidney failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • angioedema
  • angioedema
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • vertigo
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • bradycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. To maintain the drug's efficacy, it is recommended to keep it at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Brownish-red round film-coated tablet

Package unit

28 tablets/box [14 tablets/PTP×2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.